Scorpius Holdings, Inc. Completes Public Offering of Shares
DURHAM, N.C. — Scorpius Holdings, Inc. (NYSE American: SCPX), a comprehensive contract development and manufacturing organization (CDMO), has successfully finalized its underwritten public offering of 14,375,000 shares of common stock. This figure includes the complete exercise of the underwriter’s over-allotment option. Each share was priced at $1.00, leading to gross proceeds of $14,375,000 before accounting for underwriting discounts and offering expenses.
Allocation of Proceeds from the Offering
The net proceeds from this offering will primarily be directed towards enhancing working capital and supporting general corporate purposes. This strategic funding aims to strengthen the company's operational capabilities and propel its growth initiatives forward.
ThinkEquity's Role in the Offering
ThinkEquity served as the sole book-running manager for this public offering. Their deep expertise in capital markets has played a crucial role in guiding Scorpius through this process.
Regulatory Compliance and Future Prospects
A registration statement on Form S-1 regarding the securities offered was submitted to the Securities and Exchange Commission (SEC) and was approved earlier this month. The offering is being conducted solely through a prospectus. Interested individuals can obtain copies of the final prospectus directly from ThinkEquity, located at 17 State Street, 41st Floor, New York, New York 10004.
About Scorpius Holdings, Inc.
Scorpius Holdings Inc. specializes in integrated large molecule contract development and manufacturing. The company is dedicated to advancing biologic and cell therapy programs from development through to clinical application. Scorpius provides a wide range of analytical testing, process development, and manufacturing services tailored for pharmaceutical and biotech companies, all supported by its state-of-the-art facilities in San Antonio, TX. With a strong commitment to transparency and high-quality biomanufacturing, Scorpius aims to build robust collaborations with its partners.
Investor Relations Contacts
For any investor inquiries, please reach out to:
David Waldman
+1 (919)-289-4017
investorrelations@nighthawkbio.com
Frequently Asked Questions
1. What was the amount raised in the public offering by Scorpius Holdings?
Scorpius Holdings raised a total of $14,375,000 from the public offering.
2. How will the proceeds from the offering be utilized?
The proceeds will primarily be used for working capital and general corporate purposes.
3. Who managed the public offering for Scorpius Holdings?
ThinkEquity acted as the sole book-running manager for the offering.
4. Where can one obtain a copy of the final prospectus?
Copies of the final prospectus can be obtained from ThinkEquity at their office in New York.
5. What type of organization is Scorpius Holdings?
Scorpius Holdings is an integrated contract development and manufacturing organization (CDMO) focusing on biologic and cell therapy programs.